Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

R-spondin2 may help treat hair loss, gene differences could explain baldness, a peptide's regulation is linked to psoriasis, B-defensin gene copies may affect a skin condition's risk and severity, and potential markers and targets for alopecia areata were identified.

Trichoscopy is crucial for diagnosing and managing androgenetic alopecia, showing increased vellus hairs, empty follicles, and fibrosis with severity.

COVID-19 can cause temporary hair loss, often starting around 7-8 weeks after recovery, with factors like Vitamin D deficiency, other diseases, medication, and stress potentially contributing.

Hidradenitis suppurativa is a chronic skin condition causing painful lumps and scarring, often triggered by smoking and obesity, and requires varying treatments based on severity.

Androgenetic alopecia is linked to a higher risk of varicose veins, especially in men, but not to major vascular diseases.

New treatments for hair growth and psoriasis may be possible, and gene differences could affect baldness and the severity of skin conditions.

NISCH syndrome is a rare genetic disorder affecting skin and liver, with variable symptoms and limited treatment options.

Low testosterone levels may lead to more severe COVID-19 outcomes.

Long-term use of androgens can help manage Hereditary Angioedema (HAE) but may cause serious side effects, so alternative treatments with fewer side effects are being considered.

Alopecia areata treatment varies, with no optimal method established yet.

Understanding gender differences in COVID-19 is crucial for effective health strategies.

Hidradenitis suppurativa is a skin condition possibly caused by hair follicle issues, with treatments focusing on infection and inflammation.

Men and women get COVID-19 at similar rates, but men tend to get sicker and have a higher risk of dying, while women usually have stronger immune responses and vaccine reactions.

Treat alopecia areata with personalized plans, using corticosteroids for mild cases and Janus Kinase inhibitors for severe cases, while also offering psychological support.

Abrocitinib is being evaluated for safety and effectiveness in treating moderate to severe atopic dermatitis.

Topical immunotherapy with DPCP led to some hair regrowth in most pediatric alopecia areata patients, especially those with milder cases and longer treatment.

Long COVID is a big health problem needing more research and better treatments.

Experts recommend personalized treatment plans for alopecia areata, using corticosteroids and minoxidil for mild cases, and stronger medications for severe cases.

Don't ignore acne treatment to avoid scars and emotional trauma.

Testosterone's effects on COVID-19 are unclear and need more research.

Middle-aged patients, those in the Northeast, with comprehensive insurance, extensive hair loss, or additional health issues, and young or older females face higher alopecia areata medical costs.

IL-17 is more important than IFN-γ in causing severe hair loss in chronic alopecia areata.

New treatments for alopecia areata show promise, but standardized guidelines are needed.

The study suggests that a specific type of immune cell, memory-like NK cells, may increase during active hair loss in Alopecia areata.

MDSC-Exo can treat autoimmune alopecia areata and promote hair regrowth in mice.

There is no standardized treatment for hidradenitis suppurativa, and individualized plans are needed.

The study suggests smoking is common in HS patients but its role is unclear, and more research is needed to understand HS causes.

Skin inflammation can worsen intestinal inflammation and colitis.

Yellow dots are common in severe alopecia areata.

Males had more severe COVID-19 symptoms, but their risk of death was only slightly higher than females.